217 related articles for article (PubMed ID: 35897708)
1. Multiparametric Classification of Non-Muscle Invasive Papillary Urothelial Neoplasms: Combining Morphological, Phenotypical, and Molecular Features for Improved Risk Stratification.
Montes-Mojarro IA; Hassas S; Staehle S; Sander P; Harland N; Serna-Higuita LM; Bonzheim I; Bösmüller H; Stenzl A; Fend F
Int J Mol Sci; 2022 Jul; 23(15):. PubMed ID: 35897708
[TBL] [Abstract][Full Text] [Related]
2. Papillary urothelial neoplasm of low malignant potential (PUN-LMP): Still a meaningful histo-pathological grade category for Ta, noninvasive bladder tumors in 2019?
Hentschel AE; van Rhijn BWG; Bründl J; Compérat EM; Plass K; Rodríguez O; Henríquez JDS; Hernández V; de la Peña E; Alemany I; Turturica D; Pisano F; Soria F; Čapoun O; Bauerová L; Pešl M; Bruins HM; Runneboom W; Herdegen S; Breyer J; Brisuda A; Scavarda-Lamberti A; Calatrava A; Rubio-Briones J; Seles M; Mannweiler S; Bosschieter J; Kusuma VRM; Ashabere D; Huebner N; Cotte J; Mertens LS; Cohen D; Lunelli L; Cussenot O; Sheikh SE; Volanis D; Coté JF; Rouprêt M; Haitel A; Shariat SF; Mostafid AH; Nieuwenhuijzen JA; Zigeuner R; Dominguez-Escrig JL; Hacek J; Zlotta AR; Burger M; Evert M; Hulsbergen-van de Kaa CA; van der Heijden AG; Kiemeney LALM; Soukup V; Molinaro L; Gontero P; Llorente C; Algaba F; Palou J; N'Dow J; Babjuk M; van der Kwast TH; Sylvester RJ
Urol Oncol; 2020 May; 38(5):440-448. PubMed ID: 31704141
[TBL] [Abstract][Full Text] [Related]
3. Frequent FGFR3 mutations in urothelial papilloma.
van Rhijn BW; Montironi R; Zwarthoff EC; Jöbsis AC; van der Kwast TH
J Pathol; 2002 Oct; 198(2):245-51. PubMed ID: 12237885
[TBL] [Abstract][Full Text] [Related]
4. Comparison of the WHO/ISUP classification and cytokeratin 20 expression in predicting the behavior of low-grade papillary urothelial tumors. World/Health Organization/Internattional Society of Urologic Pathology.
Alsheikh A; Mohamedali Z; Jones E; Masterson J; Gilks CB
Mod Pathol; 2001 Apr; 14(4):267-72. PubMed ID: 11301341
[TBL] [Abstract][Full Text] [Related]
5. Papillary urothelial neoplasm of low malignant potential: reliability of diagnosis and outcome.
Campbell PA; Conrad RJ; Campbell CM; Nicol DL; MacTaggart P
BJU Int; 2004 Jun; 93(9):1228-31. PubMed ID: 15180612
[TBL] [Abstract][Full Text] [Related]
6. Analysis of papillary urothelial carcinomas of the bladder with grade heterogeneity: supportive evidence for an early role of CDKN2A deletions in the FGFR3 pathway.
Downes MR; Weening B; van Rhijn BW; Have CL; Treurniet KM; van der Kwast TH
Histopathology; 2017 Jan; 70(2):281-289. PubMed ID: 27530957
[TBL] [Abstract][Full Text] [Related]
7. Clinicopathologic study of 60 cases of urothelial neoplasms with inverted growth patterns: Reclassification by international consultation on urologic disease (ICUD) recommendations.
Bang H; Park H; Park S; Choi E; Cho MS; Sung SH; Choi SY; Cho YM; Jeong SU; Ro JY
Ann Diagn Pathol; 2020 Feb; 44():151433. PubMed ID: 31785538
[TBL] [Abstract][Full Text] [Related]
8. Stage progression in Ta papillary urothelial tumors: relationship to grade, immunohistochemical expression of tumor markers, mitotic frequency and DNA ploidy.
Holmäng S; Andius P; Hedelin H; Wester K; Busch C; Johansson SL
J Urol; 2001 Apr; 165(4):1124-8; discussion 1128-30. PubMed ID: 11257652
[TBL] [Abstract][Full Text] [Related]
9. Noninvasive Papillary Urothelial Carcinoma of the Bladder: An Institutional Experience Focusing on Tumors With Borderline Features.
Oliver-Krasinski JM; Bidot S; Ingram JW; O'Toole KM; McKiernan JM; Tinsley M; Harik LR
Arch Pathol Lab Med; 2024 Feb; 148(2):223-229. PubMed ID: 37134243
[TBL] [Abstract][Full Text] [Related]
10. Biologic differences between noninvasive papillary urothelial neoplasms of low malignant potential and low-grade (grade 1) papillary carcinomas of the bladder.
Pich A; Chiusa L; Formiconi A; Galliano D; Bortolin P; Navone R
Am J Surg Pathol; 2001 Dec; 25(12):1528-33. PubMed ID: 11717543
[TBL] [Abstract][Full Text] [Related]
11. Diagnostic algorithm for papillary urothelial tumors in the urinary bladder.
Shim JW; Cho KS; Choi YD; Park YW; Lee DW; Han WS; Shim SI; Kim HJ; Cho NH
Virchows Arch; 2008 Apr; 452(4):353-62. PubMed ID: 18311491
[TBL] [Abstract][Full Text] [Related]
12. Strong immunohistochemical expression of fibroblast growth factor receptor 3, superficial staining pattern of cytokeratin 20, and low proliferative activity define those papillary urothelial neoplasms of low malignant potential that do not recur.
Barbisan F; Santinelli A; Mazzucchelli R; Lopez-Beltran A; Cheng L; Scarpelli M; van der Kwast T; Montironi R
Cancer; 2008 Feb; 112(3):636-44. PubMed ID: 18072261
[TBL] [Abstract][Full Text] [Related]
13. Molecular and clinical support for a four-tiered grading system for bladder cancer based on the WHO 1973 and 2004 classifications.
van Rhijn BW; Musquera M; Liu L; Vis AN; Zuiverloon TC; van Leenders GJ; Kirkels WJ; Zwarthoff EC; Boevé ER; Jöbsis AC; Bapat B; Jewett MA; Zlotta AR; van der Kwast TH
Mod Pathol; 2015 May; 28(5):695-705. PubMed ID: 25431236
[TBL] [Abstract][Full Text] [Related]
14. Diagnostic and Prognostic Implications of FGFR3
Geelvink M; Babmorad A; Maurer A; Stöhr R; Grimm T; Bach C; Knuechel R; Rose M; Gaisa NT
Int J Mol Sci; 2018 Aug; 19(9):. PubMed ID: 30154342
[TBL] [Abstract][Full Text] [Related]
15. Mutational Analysis of 472 Urothelial Carcinoma Across Grades and Anatomic Sites.
Nassar AH; Umeton R; Kim J; Lundgren K; Harshman L; Van Allen EM; Preston M; Dong F; Bellmunt J; Mouw KW; Choueiri TK; Sonpavde G; Kwiatkowski DJ
Clin Cancer Res; 2019 Apr; 25(8):2458-2470. PubMed ID: 30593515
[TBL] [Abstract][Full Text] [Related]
16. Biological significance of TERT promoter mutation in papillary urothelial neoplasm of low malignant potential.
Wang CC; Huang CY; Jhuang YL; Chen CC; Jeng YM
Histopathology; 2018 Apr; 72(5):795-803. PubMed ID: 29193225
[TBL] [Abstract][Full Text] [Related]
17. Keratin 17 is a sensitive and specific biomarker of urothelial neoplasia.
Babu S; Mockler DC; Roa-Peña L; Szygalowicz A; Kim NW; Jahanfard S; Gholami SS; Moffitt R; Fitzgerald JP; Escobar-Hoyos LF; Shroyer KR
Mod Pathol; 2019 May; 32(5):717-724. PubMed ID: 30443013
[TBL] [Abstract][Full Text] [Related]
18. Molecular grading of urothelial cell carcinoma with fibroblast growth factor receptor 3 and MIB-1 is superior to pathologic grade for the prediction of clinical outcome.
van Rhijn BW; Vis AN; van der Kwast TH; Kirkels WJ; Radvanyi F; Ooms EC; Chopin DK; Boevé ER; Jöbsis AC; Zwarthoff EC
J Clin Oncol; 2003 May; 21(10):1912-21. PubMed ID: 12743143
[TBL] [Abstract][Full Text] [Related]
19. Noninvasive low-grade papillary urothelial carcinoma with degenerative nuclear atypia: a grading pitfall.
Matoso A; Parimi V; Epstein JI
Hum Pathol; 2021 Jul; 113():1-8. PubMed ID: 33887303
[TBL] [Abstract][Full Text] [Related]
20. Study of mutated p53 protein by immunohistochemistry in urothelial neoplasm of urinary bladder.
Roychowdhury A; Dey RK; Bandyapadhyay A; Bhattacharya P; Mitra RB; Dutta R
J Indian Med Assoc; 2012 Jun; 110(6):393-6. PubMed ID: 23360043
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
